JP2019514998A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514998A5 JP2019514998A5 JP2018559221A JP2018559221A JP2019514998A5 JP 2019514998 A5 JP2019514998 A5 JP 2019514998A5 JP 2018559221 A JP2018559221 A JP 2018559221A JP 2018559221 A JP2018559221 A JP 2018559221A JP 2019514998 A5 JP2019514998 A5 JP 2019514998A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- sucrose
- pharmaceutical composition
- binding fragment
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 229930006000 Sucrose Natural products 0.000 claims 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 11
- 239000005720 sucrose Substances 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 10
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 5
- 229920000053 polysorbate 80 Polymers 0.000 claims 5
- 229940068968 polysorbate 80 Drugs 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 4
- 239000004094 surface-active agent Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1608323.0 | 2016-05-12 | ||
| GBGB1608323.0A GB201608323D0 (en) | 2016-05-12 | 2016-05-12 | Pharmaceutical compositions |
| PCT/EP2017/061261 WO2017194646A1 (en) | 2016-05-12 | 2017-05-11 | Pharmaceutical composition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019514998A JP2019514998A (ja) | 2019-06-06 |
| JP2019514998A5 true JP2019514998A5 (enExample) | 2020-05-21 |
| JP7126454B2 JP7126454B2 (ja) | 2022-08-26 |
Family
ID=56320265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559221A Active JP7126454B2 (ja) | 2016-05-12 | 2017-05-11 | 医薬組成物 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11407835B2 (enExample) |
| EP (1) | EP3454899B1 (enExample) |
| JP (1) | JP7126454B2 (enExample) |
| KR (1) | KR102436694B1 (enExample) |
| CN (1) | CN109069643A (enExample) |
| AR (1) | AR108449A1 (enExample) |
| AU (1) | AU2017264553A1 (enExample) |
| BR (1) | BR112018072264A2 (enExample) |
| CA (1) | CA3022124A1 (enExample) |
| CL (1) | CL2018003178A1 (enExample) |
| CO (1) | CO2018011733A2 (enExample) |
| EA (1) | EA201892446A1 (enExample) |
| ES (1) | ES2977545T3 (enExample) |
| GB (1) | GB201608323D0 (enExample) |
| IL (1) | IL262654A (enExample) |
| MX (1) | MX2018013215A (enExample) |
| SG (1) | SG11201809229VA (enExample) |
| WO (1) | WO2017194646A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110251675A (zh) | 2013-05-03 | 2019-09-20 | 西莱克塔生物科技公司 | 降低或预防响应于非变应原性抗原的过敏反应的致耐受性合成纳米载体 |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| ES3036482T3 (en) | 2017-03-11 | 2025-09-19 | Cartesian Therapeutics Inc | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| GB201708655D0 (en) * | 2017-05-31 | 2017-07-12 | Ucb Biopharma Sprl | Cell culture methods |
| WO2019180261A1 (en) * | 2018-03-23 | 2019-09-26 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| AU2020287627A1 (en) | 2019-06-04 | 2021-11-18 | Selecta Biosciences, Inc. | Formulations and doses of PEGylated uricase |
| AU2021236234A1 (en) * | 2020-03-11 | 2022-10-06 | Selecta Biosciences, Inc. | Methods and compositions related to synthetic nanocarriers |
| CN115776879A (zh) * | 2020-06-29 | 2023-03-10 | 韩兀生物制药股份有限公司 | 抗fcrn抗体制剂 |
| CN117615788A (zh) * | 2021-05-12 | 2024-02-27 | 安奈普泰斯生物有限公司 | 抗体组合物 |
| CN118317787A (zh) | 2021-12-01 | 2024-07-09 | Ucb生物制药有限责任公司 | 包含Fab-PEG的制剂 |
| CN119233815A (zh) * | 2022-05-20 | 2024-12-31 | 株式会社大赛璐 | 液态医药组合物 |
| AU2023281650A1 (en) | 2022-05-30 | 2024-10-17 | Hanall Biopharma Co., Ltd. | Anti-fcrn antibody or antigen binding fragment thereof with improved stability |
| CN115708810A (zh) * | 2022-11-03 | 2023-02-24 | 浙江新码生物医药有限公司 | 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途 |
| EP4676963A1 (en) * | 2023-03-08 | 2026-01-14 | Immunovant Sciences GmbH | High concentration protein formulations with polysorbate excipients and methods of making the same |
| WO2025056011A1 (zh) * | 2023-09-13 | 2025-03-20 | 正大天晴药业集团股份有限公司 | 包含抗pd-1抗体和第二抗体的药物组合物 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003009817A2 (en) * | 2001-07-25 | 2003-02-06 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
| CA2545603A1 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
| WO2007132480A2 (en) * | 2006-05-12 | 2007-11-22 | Bharat Biotech International Limited | A composition useful as a vaccine |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| AR070315A1 (es) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| CN102695499A (zh) | 2009-06-18 | 2012-09-26 | 惠氏有限责任公司 | 小模块免疫药物的冻干制剂 |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| US8788028B2 (en) | 2010-07-28 | 2014-07-22 | Medtronic, Inc. | Parasympathetic stimulation to enhance tachyarrhythmia detection |
| US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
| CA2830806C (en) | 2011-03-31 | 2020-05-12 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| RU2644214C2 (ru) | 2012-03-26 | 2018-02-08 | Санофи | СТАБИЛЬНЫЕ ПРЕПАРАТЫ СВЯЗЫВАЮЩЕГО СРЕДСТВА НА ОСНОВЕ IgG4 |
| US9592289B2 (en) * | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| GB201208370D0 (en) * | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| US8613919B1 (en) | 2012-08-31 | 2013-12-24 | Bayer Healthcare, Llc | High concentration antibody and protein formulations |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| US20150307606A1 (en) | 2012-12-13 | 2015-10-29 | Ashwin Basarkar | Lyophilized spherical pellets of anti-il-23 antibodies |
| TW201542226A (zh) | 2014-02-12 | 2015-11-16 | Sanofi Sa | 抗－ｉｌ－４／抗－ｉｌ－１３雙特異性抗體／聚麩胺酸配製物 |
| BR112017007393A2 (pt) | 2014-10-18 | 2017-12-19 | Pfizer | composições de anticorpo anti-il-7r |
| GB201508180D0 (en) | 2015-05-13 | 2015-06-24 | Ucb Biopharma Sprl | Antibodies |
-
2016
- 2016-05-12 GB GBGB1608323.0A patent/GB201608323D0/en not_active Ceased
-
2017
- 2017-05-11 AU AU2017264553A patent/AU2017264553A1/en not_active Abandoned
- 2017-05-11 SG SG11201809229VA patent/SG11201809229VA/en unknown
- 2017-05-11 EA EA201892446A patent/EA201892446A1/ru unknown
- 2017-05-11 CA CA3022124A patent/CA3022124A1/en active Pending
- 2017-05-11 BR BR112018072264-2A patent/BR112018072264A2/pt not_active IP Right Cessation
- 2017-05-11 US US16/300,522 patent/US11407835B2/en active Active
- 2017-05-11 ES ES17725544T patent/ES2977545T3/es active Active
- 2017-05-11 MX MX2018013215A patent/MX2018013215A/es unknown
- 2017-05-11 EP EP17725544.5A patent/EP3454899B1/en active Active
- 2017-05-11 CN CN201780028404.3A patent/CN109069643A/zh active Pending
- 2017-05-11 KR KR1020187036132A patent/KR102436694B1/ko active Active
- 2017-05-11 JP JP2018559221A patent/JP7126454B2/ja active Active
- 2017-05-11 AR ARP170101248A patent/AR108449A1/es not_active Application Discontinuation
- 2017-05-11 WO PCT/EP2017/061261 patent/WO2017194646A1/en not_active Ceased
-
2018
- 2018-10-28 IL IL262654A patent/IL262654A/en unknown
- 2018-10-30 CO CONC2018/0011733A patent/CO2018011733A2/es unknown
- 2018-11-08 CL CL2018003178A patent/CL2018003178A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019514998A5 (enExample) | ||
| RU2019100887A (ru) | Композиции антитела и белка | |
| JP2016534052A5 (enExample) | ||
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| EA201892446A1 (ru) | Фармацевтическая композиция | |
| JP2014514346A5 (enExample) | ||
| HRP20212028T1 (hr) | Postupci za liječenje hiperlipidemije inhibitorom angptl8 i inhibitorom angptl3 | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| FI3408295T3 (fi) | Bispesifisiä vasta-ainekonstrukteja käsittävä farmaseuttinen koostumus | |
| JP2016515511A5 (enExample) | ||
| RU2015120605A (ru) | Стабильная композиция белка иммуноглобулина с двойными вариабельными доменами | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| EA033387B1 (ru) | СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2 | |
| JP2020536109A5 (enExample) | ||
| PE20190975A1 (es) | Novela cd47 anticuerpos monoclonales y sus usos | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| HRP20190672T1 (hr) | Konjugirane formulacije anti-egfr protutijelo-lijek | |
| RU2014140137A (ru) | Лекарственный препарат антитела к бета-амилоиду | |
| HRP20220918T1 (hr) | Anti-transtiretinska antitijela | |
| PE20171512A1 (es) | Anticuerpos anti-fap | |
| JP2017113019A5 (enExample) | ||
| HRP20110334T1 (hr) | PROTUTIJELA SPECIFIČNA ZA TGF-ß1 | |
| RU2019100221A (ru) | Составы на основе антитела к CD19 | |
| RU2011142184A (ru) | Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами | |
| JP2017529097A5 (enExample) |